// App-Quantinova.ai

4512 : Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC) Expanded efficacy analyses from KEYNOTE-564.

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Se Hoon Park

  • Balaji Venugopal

  • Tom Ferguson

  • Stefan N. Symeonides

  • Jaroslav Hajek

  • Yen-Hwa Chang

  • Jae-Lyun Lee

  • Naveed Sarwar

  • Antoine Thiery-Vuillemin

  • Marine Gross-Goupil

  • Mauricio Mahave

  • Naomi B. Haas

  • Piotr Sawrycki

  • Howard Gurney

  • Lei Xu

  • Kentaro Imai

  • Jackie Rogerio

  • Thomas Powles

Medical Centers

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Poznan University of Medical Sciences, Poznan, Poland

  • Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea

  • Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, United Kingdom

  • Fiona Stanley Hospital, Perth, Australia

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

  • Fakultni Nemocnice Ostrava, Ostrava, Czech Republic

  • Taipei Veterans General Hospital, Taipei City, Taiwan

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Imperial College, London, United Kingdom

  • Uiniversity Hospital Minjoz, Besancon, France

  • University Hospital of Bordeaux-St. Andrews Hospital, Bordeaux, France

  • Fundacion Arturo Lopez Perez, Santiago, Chile

  • Abramson Cancer Center, Penn Medicine, Philadelphia, PA

  • Provincial Hospital in Torun, Torun, Poland

  • Macquarie University Hospital, Sydney, Australia

  • Merck & Co., Inc., Kenilworth, NJ

  • Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United States

  • Poland

  • Republic of South Korea

  • United Kingdom

  • Australia

  • Czech Republic

  • Taiwan

  • France

  • Chile

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Clear cell renal carcinoma

  • Solid malignancies

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03142334

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved